Q-omics provides the consensus-scored SULT1D1P profile across patient tissues and cancer cell-line models. SULT1D1P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SULT1D1P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, SULT1D1P RNA expression shows 9,844 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, STAD, and TGCT as cancer lineages where SULT1D1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT1D1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT1D1P survival associations across molecular data types. SULT1D1P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT1D1P RNA expression–survival associations across cancer types. High SULT1D1P expression shows unfavorable associations in MESO, KIRP, KIRC, OV and BRCA, but favorable associations in BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SULT1D1P RNA expression.
This table summarizes SULT1D1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SULT1D1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT1D1P shows higher tumor expression in STAD, COAD and READ. The STAD box plot shows higher SULT1D1P RNA expression in tumor versus normal tissue (log2 FC = +0.098, t-test p = .005).
This table shows molecular features associated with SULT1D1P in patient tissues and cancer cell lines. In patient samples, SULT1D1P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
